Open Access<p>Clinical Determinants of Successful Omalizumab Therapy in Severe Allergic Asthma Patients: 4-Year-Long, Real-Life Observation</p>
Author(s) -
Aleksandra Kucharczyk,
Ewa Więsik-Szewczyk,
Anna Poznańska,
Karina JahnzRóżyk
Publication year - 2020
Publication title -
journal of asthma and allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.162
H-Index - 30
ISSN - 1178-6965
DOI - 10.2147/jaa.s282203
Subject(s) - omalizumab , medicine , asthma , allergic asthma , retrospective cohort study , pediatrics , physical therapy , immunoglobulin e , immunology , antibody
Omalizumab is a high-cost therapy recommended for the treatment of severe allergic asthma.